Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. [electronic resource]
Producer: 20120106Description: 1066-74 p. digitalISSN:- 1879-355X
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Alkylating -- adverse effects
- Brain Neoplasms -- mortality
- Chemoradiotherapy -- adverse effects
- Chemotherapy, Adjuvant
- Dacarbazine -- adverse effects
- Dose Fractionation, Radiation
- Drug Administration Schedule
- Female
- Glioblastoma -- mortality
- Humans
- Karnofsky Performance Status
- Magnetic Resonance Imaging
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Recurrence, Local -- surgery
- Neoplasm, Residual
- Prospective Studies
- Radiotherapy, Intensity-Modulated -- adverse effects
- Temozolomide
- Tumor Burden
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.